(BW)(CT-IMS-HEALTH)(RX) IMS公司在下一代测量服务计划——“新模式、新标准”下首推新服务

MIDAS Market Segmentation为非专利药品的量度树立全球新标准，达到保护细分市场的目标

美国商业资讯2006年11月6日康涅狄格州费尔菲尔德消息——

全球领先的医药保健行业市场情报资源提供商IMS Health公司（纽约证券交易所：RX）今日宣布了一项综合性的全球计划——“新模式、新标准”，来为医药保健行业提供下一代市场测量服务。IMS的计划包含一系列创新性举措，有助于转变公司的核心信息资产，帮助客户在变幻莫测的市场风云中做出更为自信的决策。

IMS公司执行副总裁Gilles Pajot说：“受专业产品、新渠道、付款压力、新兴市场，尤其是非专利药品增长的影响，医药市场的形势在近些年发生了显著变化。医疗保健行业的这些变化暗含着深远的意义。只有IMS能够提供全面、持续性的信息集合、分析和咨询服务，以及全球到本地的投放能力，协助客户深入理解不断发展的市场动态，形成新型的商业模式和战略。”

“新模式、新标准”计划下首次推出的MIDAS Market Segmentation(TM)是一项全球性新标准，针对测量与分析非专利药品细分市场，了解专利过期后产品的市场机遇和表现。该服务使人们能够前所未有的预见到在产品是否经受专利、市场垄断以及其他因素“保护”的形势下市场的构成、规模及增长。通过对非专利药品市场动态和有关专利保护形势下更广阔的市场发展动态快速而稳定的把握，MIDAS Market Segmentation能够帮助药品生产商更加明确自身产品组合的潜在优势。

借助MIDAS Market Segmentation，IMS公司将非专利类药品化分成几种常规类型，并将整个医药市场进行了重新分类，为每种产品指定了专门的知识产权保护等级，这对指导与带动客户进行关键性的商业决策来说将是一项功能强大的服务。通过将该服务与IMS的分析咨询服务进行结合，IMS能够帮助客户进一步加强预测、场景建模、竞争基准和组合规划活动，从而强化自己的优势地位。

该服务的开发离不开IMS公司客户的紧密协作和主要的医药与非专利药品行业协会的参与。目前该服务已向美国、加拿大、欧洲11个国家（德国、意大利、西班牙、法国、英国、比利时、荷兰和北欧国家）以及南非等地开放。MIDAS Market Segmentation将于2007年全年向另外13个欧洲国家和日本地区进行全面投放。

“新模式、新标准”下的未来服务将专注于新兴市场、平行贸易、专业渠道、疾病与治疗模式，以及其它发展变化的市场领域。

关于IMS公司

IMS Health公司业务遍及100多个国家，是医药和保健行业全球领先的市场情报资源提供商。2005年，IMS公司收入达18亿美元；这家拥有50多年历史的企业提供一流的商业情报产品和服务，满足客户的日常经营需求，其中包括：产品组合优化服务；产品上市和品牌管理解决方案；销售人员效率创新；管理式医保和非处方（OTC）产品，以及咨询和服务解决方案，能够提高全球优质保健服务的投资回报率，改善产品供应水平。如需了解更多信息，请访问： http://www.imshealth.com 。

前瞻性声明

本新闻稿中的一些声明，依照1995年《私人证券诉讼修正法案》中的免责条款可能构成了前瞻性声明。尽管IMS Health公司认为此类前瞻性声明所阐述的一些预期具有一定的合理性，但公司无法保证此类预期的完全准确性。这些信息可能包含一些风险和不确定性因素，这些风险和不确定性因素可能导致IMS Health公司的实际业绩与这些前瞻性声明中所述的内容有着重大的差异。可能引起或导致此类差异的因素包括但不局限于（1）与全球运营有关的风险，包括与美元相关的外汇价值的波动，成功规避此类风险的能力；（2）特别是在数据存取利用和税收方面的调整、立法、及执法活动；（3）不可预见的现金需求增加的程度，获取有利资金的能力；（4）IMS Health公司通过收购和合资寻求成长的力度，确立、完成以及整合收购及合资达到满意程度的能力；（5）为其业务及时并高性价比地开发新的或先进的技术及系统的能力；（6）特别是在医药、保健或IMS Health公司客户经营的其他领域中经济环境的恶化。有关可能影响公司业务和收入因素的其他信息可在公司有时提交给美国证券交易委员会的文件中查阅。

联系方式：IMS公司通信部 Clive Savage，+44 20 3075 5311 csavage@uk.imshealth.com 或者 Lance Longwell，610-834-5338 llongwell@us.imshealth.com

(BW)(CT-IMS-HEALTH)(RX) IMS Launches First Offering Under 'New Models, New Metrics' Program of Next-Generation Measurement Services

MIDAS Market Segmentation Establishes New Global Standard For Measuring Generics, Protected Market Segments

FAIRFIELD, Conn.--(BUSINESS WIRE)--Nov. 6, 2006--

IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced a comprehensive global program - New Models, New Metrics - to provide the next generation of market measurement services to the pharmaceutical and healthcare industries. The program encompasses a number of IMS initiatives that are transforming the company's core information assets, helping clients make more confident decisions as they address increasingly complex market dynamics.

"The landscape of the pharmaceutical marketplace has changed dramatically in recent years, driven by specialty products, new channels, payer pressures, emerging markets and, especially, generics growth," said Gilles Pajot, executive vice president, IMS. "The implications of these changes for the healthcare and pharmaceutical industries are profound. Only IMS brings a full continuum of information, analytics and consulting capabilities - as well as 'global-to-local' reach - to help clients gain a deep understanding of evolving market dynamics as they shape new business models and strategies."

The first launch under New Models, New Metrics is MIDAS Market Segmentation(TM), a new global standard for measuring and analyzing the generics market segment, and for understanding market opportunities and the performance of products beyond patent expiration. The offering delivers unprecedented visibility to the composition, size and growth of the market based on whether products are "protected" by patents, market exclusivity or other factors. MIDAS Market Segmentation enables pharmaceutical manufacturers to more clearly define the underlying performance of their product portfolios by quickly and consistently characterizing the dynamics of the generics market, as well as the broader market in terms of patent protection status.

With MIDAS Market Segmentation, IMS has categorized generics products into consistent types and reclassified the overall pharmaceutical market, assigning a specific intellectual property protection status to each product, a powerful component to guiding and driving clients' key commercial decisions. By combining this offering with IMS's analytical and consulting capabilities, IMS is better positioned to help clients further improve their forecasting, scenario modeling, competitive benchmarking and portfolio planning activities.

The offering was developed in close collaboration with IMS clients, along with major pharmaceutical and generics industry associations. It is now available in the U.S., Canada, 11 EU countries - Germany, Italy, Spain, France, UK, Belgium, The Netherlands and the Nordic countries - and in South Africa. MIDAS Market Segmentation will be rolled out throughout 2007 to an additional 13 European countries and Japan.

Future offerings under New Models, New Metrics will address emerging markets, parallel trade, specialty channels, disease and treatment patterns, and other evolving market dynamics.

About IMS

Operating in more than 100 countries, IMS Health is the world's leading provider of market intelligence to the pharmaceutical and healthcare industries. With $1.8 billion in 2005 revenue and more than 50 years of industry experience, IMS offers leading-edge business intelligence products and services that are integral to clients' day-to-day operations, including portfolio optimization capabilities; launch and brand management solutions; sales force effectiveness innovations; managed care and over-the-counter offerings; and consulting and services solutions that improve ROI and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com .

Forward-Looking Statements

This press release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although IMS Health believes the expectations contained in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. This information may involve risks and uncertainties that could cause actual results of IMS Health to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to (i) the risks associated with operating on a global basis, including fluctuations in the value of foreign currencies relative to the U.S. dollar, and the ability to successfully hedge such risks, (ii) regulatory, legislative and enforcement initiatives, particularly in the areas of data access and utilization and tax, (iii) to the extent unforeseen cash needs arise, the ability to obtain financing on favorable terms, (iv) to the extent IMS Health seeks growth through acquisitions and joint ventures, the ability to identify, consummate and integrate acquisitions and joint ventures on satisfactory terms, (v) the ability to develop new or advanced technologies and systems for its businesses on time and on a cost-effective basis, and (vi) deterioration in economic conditions, particularly in the pharmaceutical, healthcare or other industries in which IMS Health's customers operate. Additional information on factors that may affect the business and financial results of the Company can be found in the filings of the company made from time to time with the Securities and Exchange Commission.

CONTACT: IMS Communications Clive Savage, +44 20 3075 5311 csavage@uk.imshealth.com or Lance Longwell, 610-834-5338 llongwell@us.imshealth.com